COPD Post-Market Requirements: Cardiovascular Safety Could Evolve to Comparative Trials
This article was originally published in RPM Report
Forest's aclidinium breezed through an advisory committee review with three strong votes in favor of approval. The FDA panel, however, also included an interesting call for more head-to-head trials in COPD from the outgoing panel chair. That may impact Forest's Phase IV work--but more importantly it may be a sign of the future expectations for other sponsors in the active COPD development area.
You may also be interested in...
The current tool by which patients with lungs diseases (like asthma and COPD) measure their own lung function at home, the peak expiratory flow meter, is not sufficiently informative enough to guide decision-making. PMD Healthcare aims to help respiratory patients care for their disease better. The company has developed a spirometer for home use, Spiro PD, that works on the same principles as the well-accepted office-based and hospital spirometers, but is easy to use and affordable.
As FDA girds for the Capitol Hill phase of the user fee reauthorization push in 2012, the agency is projecting an image as a flexible problem-solver. FDA’s underlying message: the agency has sufficient authority and does not need tinkering with the legislative mandate. From the drug industry’s perspective, a continued stress on flexibility through the first nine months of the year could create a favorable climate for application reviews and for resolving lingering manufacturing issues.
The Division of Pulmonary-Allergy Drugs has seen a number of high profile drugs come through its review group. The RPM Report sat down with Division Director Badrul Chowdhury to talk about his philosophy of drug review, the REMS, biosimilars, and the role of drug safety in making approval decisions.